Skip to main
FOLD
FOLD logo

Amicus Therapeutics (FOLD) Stock Forecast & Price Target

Amicus Therapeutics (FOLD) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Amicus Therapeutics Inc exhibits a strong positive outlook due to the continuous double-digit year-over-year growth of Galafold sales, indicating robust demand for its products even after a decade on the market. Additionally, advancements in diagnostic testing fueled by artificial intelligence and machine learning are expected to expand the addressable market for Fabry disease, presenting further growth opportunities. The encouraging results of Atacicept in the treatment of IgA nephropathy (IgAN) enhance the company's potential to successfully diversify its rare disease portfolio, reinforcing its commitment to addressing significant unmet medical needs.

Bears say

Amicus Therapeutics faces challenges related to its product sparsentan, particularly in the treatment of FSGS patients where the drug may offer little benefit due to specific disease mechanisms involving high levels of MCP-1, which correlate with poor kidney function and increased proteinuria. Despite the large potential addressable market of approximately 40,000 patients in the U.S. and the absence of existing FDA-approved therapies for FSGS, investor perception seems overly optimistic regarding the prospects of this therapy. The repeated emphasis on the limitations of sparsentan suggests a fundamental concern about the company's ability to effectively capture and leverage this market opportunity, impacting overall financial confidence.

Amicus Therapeutics (FOLD) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amicus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amicus Therapeutics (FOLD) Forecast

Analysts have given Amicus Therapeutics (FOLD) a Buy based on their latest research and market trends.

According to 8 analysts, Amicus Therapeutics (FOLD) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amicus Therapeutics (FOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.